Last updated: April 25, 2026
Who Supplies Ceritinib to the Pharmaceutical Supply Chain?
Ceritinib is a small-molecule oncology drug (Zykadia). The supply chain is split between (1) API manufacturing and (2) finished-dose and commercial distribution. The most relevant “supplier” question for R&D and procurement is therefore: who makes the ceritinib API and who supplies the finished drug product.
Which companies supply ceritinib API?
The ceritinib API is supplied by multiple manufacturers used across branded and generic markets. In practice, procurement sources include: contract manufacturers (CMOs) for API and API traders/distributors that package API from one or more primary producers for downstream formulators.
Common ceritinib API supply channels
- API manufacturers (primary producers): produce ceritinib as the active ingredient for generic and branded relabel products.
- CMOs and contract suppliers: manufacture ceritinib API under customer-specific registrations and supply agreements.
- API distributors/traders: source API from primary producers and sell into formulation and repack channels.
Practical note for procurement: finished-dose procurement often identifies the approved drug product distribution network, while API procurement tracks directly to API DMFs/EDMFs and to the company names listed on regulatory submissions.
Who supplies the finished drug product (Zykadia) and generic ceritinib?
In commercial markets, the finished product supplier depends on whether you procure the branded product (Zykadia) or a generic equivalent.
- Branded product: Zykadia is marketed by Novartis in multiple jurisdictions through its local affiliates and distribution partners.
- Generic products: supplied by generic manufacturers in each market where approved generics exist. Generic supplier identities vary by country, dosage strength, and approval status.
Because “supplier” is jurisdiction- and strength-specific, the accurate procurement list is built from:
1) national drug registries (marketing authorization holders),
2) product labeling (MAH and distributor on-country), and
3) pharmacy wholesaler supply chain listings.
What procurement-ready supplier data can be extracted for ceritinib?
Where do you verify suppliers?
For drug product, supplier verification relies on marketing authorization records and labeling. For API, it relies on DMF/EDMF submissions and API listing on regulatory files.
Verification sources used in pharmaceutical sourcing
- National drug registries and product labels (finished-dose MAH and distributor)
- Regulatory listings tied to API dossiers (DMF/EDMF holders and manufacturing sites)
- Wholesaler catalogs in the target country (saleable SKU supplier identity)
How do you map ceritinib strengths to supplier SKUs?
Ceritinib is commonly supplied in multiple strengths. Supplier and availability often change by strength and packaging configuration.
Operational mapping method
- Start with the target market country
- Pull approved dosage strengths for ceritinib
- Match those strengths to MAH/distributor records for finished-dose procurement
- For API procurement, map the product’s approved suppliers back to API dossier holders
Key Takeaways
- Ceritinib supply splits into API suppliers (primary API manufacturers and CMOs) and finished-dose suppliers (brand MAH/distributors and local generic MAHs).
- Novartis supplies the branded product Zykadia through market-specific affiliates and distributors.
- The supplier roster for ceritinib must be built by country and dosage strength using drug registry and regulatory dossier records.
- API sourcing is verified through DMF/EDMF holders tied to manufacturing sites, not just through commercial distributors.
FAQs
-
Is ceritinib supplied mainly by one manufacturer globally?
No. Ceritinib is supplied through multiple API manufacturers/CMOs and multiple finished-dose MAHs across countries.
-
Who is the supplier for the branded ceritinib product Zykadia?
Novartis markets Zykadia.
-
How do procurement teams identify the right ceritinib API supplier?
They match the target product’s regulatory dossier to the API DMF/EDMF holder and the listed manufacturing site.
-
Do ceritinib suppliers change by dosage strength?
Yes. Finished-dose supplier identity and availability can vary by strength and packaging configuration in each market.
-
What is the most reliable way to list ceritinib suppliers for a specific market?
Use the target country’s marketing authorization records and labeling, then cross-check API dossier information for formulation readiness.
References
[1] Novartis. Zykadia (ceritinib) product information (varies by jurisdiction).
[2] U.S. FDA. Drug shortages database and drug labeling references for ceritinib products (if applicable to specific entries).
[3] EMA. EPAR and related documents for ceritinib (market authorization holder and product details).
[4] EMA/EDQM. European public assessment and dossier metadata for ceritinib medicines (jurisdiction-specific).
